Herantis Pharma Plc’s directed share issue and share subscription by Broadview Ventures I, LLC
Herantis Pharma Plc
Stock exchange release 14 January 2016, 10:00 am
The Board of Directors of Herantis Pharma Plc has decided on a directed share issue to Broadview Ventures I, LLC based on authorization by the company’s annual meeting of shareholders and according to a subscription agreement between the parties. Broadview Ventures I, LLC has fully subscribed to this share issue, total of 32,311 new shares in Herantis Pharma Plc for a subscription price of EUR 10.00 per share.
The new shares have been registered in the Trade Register on 12 January 2016, as of which date the new shares will establish shareholder rights.
The share capital will not increase with subscriptions. The entire subscription price of EUR 323,110.00 will be entered in the invested unrestricted equity reserve of the company. As a result of the share subscriptions, the number of shares of Herantis Pharma Plc will increase to 4,118,305 shares.
The new shares will be traded on the NASDAQ OMX Helsinki Ltd’s First North marketplace together with the old shares as of today, 14 January 2016.
Share information of the Herantis Pharma Plc share after the registration of the new shares:
Trading Code: HRTIS
ISIN code: FI4000087861
List: First North Helsinki
Industry: Health Care
Number of Shares: 4,118,305
Share Capital: 80,000.00 euro
Herantis Pharma Plc.
Herantis Pharma Plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246
About Herantis Pharma Plc
Herantis Pharma Plc is a pharmaceutical company specialised in new drug research and development. The company focuses on diseases with an unmet clinical need. These diseases include for example Parkinson’s disease and secondary lymphedema. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.